Skip to main content
A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
The International Neuroblastoma Pathology Classification (the Shimada system).
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
Neuroblastoma in adults and adolescents: an indolent course with poor survival.
p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment.
Elevated IGA in carcinoma of the nasopharynx.